Pemvidutide

Pemvidutide is a dual GLP-1 / glucagon agonist. Instead of GIP, it adds glucagon receptor activity, which increases energy expenditure and acts directly on the liver to burn fat. Retatrutide is a triple agonist that adds both GIP and glucagon, while tirzepatide is a GLP-1 / GIP dual agonist. Pemvidutide's balanced roughly 1:1 GLP-1 to glucagon ratio is tuned specifically for liver fat clearance and lean mass preservation.

In the 48-week MOMENTUM Phase 2 obesity trial (391 subjects), mean weight loss reached 10.3%, 11.2%, and 15.6% at the 1.2mg, 1.8mg, and 2.4mg weekly doses versus 2.2% for placebo. More than 30% of the 2.4mg group lost at least 20% of body weight. These figures come from Altimmune's readout and an ADA conference presentation, not yet a peer-reviewed publication.

In MOMENTUM, roughly 21.9% of the weight lost on pemvidutide was lean mass, meaning close to 78% came from fat. That ratio is favorable next to typical GLP-1 monotherapy, where lean mass often accounts for a larger share of loss. The result is promising but comes from a single Phase 2 trial reported at conference, so it needs confirmation in larger peer-reviewed studies.

In the Phase 1b MASLD study (Harrison et al., Journal of Hepatology 2025), pemvidutide cut liver fat content by up to about 76% relative to baseline. In the Phase 2b IMPACT trial (Noureddin et al., Lancet 2025), 24-week MASH resolution without worsening fibrosis reached 59.1% at 1.2mg and 52.1% at 1.8mg versus 19.1% for placebo, though the separate fibrosis-improvement endpoint was not met at 24 weeks.

No. Pemvidutide (ALT-801) is investigational and not approved for any use. It remains in Phase 2 development for obesity and MASH, and Altimmune has reported an end-of-Phase 2 alignment with the FDA to advance toward Phase 3 in MASH. It is available for research purposes only.

Trials used once-weekly subcutaneous injection, titrated upward to 1.2, 1.8, or 2.4mg to limit nausea and GI effects. For reconstitution, bacteriostatic water is standard: adding 2mL to a 10mg vial yields 5mg/mL. Swirl gently, do not shake, and store refrigerated at 2-8°C after mixing.